AiDi Injection Combined With Irinotecan Puls Cisplatin For Treatment Of Small Cell Lung Cancer And Evaluation Of Pharmacoeconomic

Objective To observe the clinical effect of improving the quality of life,reducing the toxicity of AiDi injection combined with IP(irinotecan puls cisplatin)in treatment of patients with small cell lung cancer(SCLC),and to conduct the pharmacoeconomic evaluation.Methods The hospitalized patients from January 2016 to December 2017 were divided into a experimental group(Aidi combined with IP program)and a control group(simple IP protocol)using a retrospective analysis method.Each group was treated for 4 cycles.Disease control rate,Karnofsky(KPS)functional status scoring criteria,short-term efficacy,immune function,adverse drug reactions in each group,and pharmacoeconomic analysis using cost-effective methodsResults Among the two groups of patients,51 patients in the experimental group completed the design,the effective rate was 35.3%,and 50 patients in the control group completed the design,the effective rate was 26.0%(P=0.311),and the disease control rate of the experimental group was 78.4%,the control group was 70.0%(P=0.333),and there was no significant difference..After treatment,two groups KPS score increase rates were 62.7%,34.0%respectively,with significant difference(P=0.004).In liver function,the alanine aminotransferase(ALT)and aspartate aminotransferase(AST)of the experimental group were significantly different from the control group(P = 0.001 and P = 0.000).However,there was no significant difference in total bilirubin,indirect bilirubin and direct bilirubin(P=0.251,P=0.063 and P=0.118).Among the renal functions,the urea nitrogen and creatinine clearance rates of the experimental group were not significantly different from those of the control group(P=0.486 and P=0.200).In the experimental group,Ⅰ～Ⅳ degree of leukopenia,thrombocytopenia,neutropenia and incidence of adverse reactions such as nausea and vomiting were49.0%、52.9%、39.2%、39.2%,and lower than the control group(80.0%、80.0%、70.0%、70.0%respectively),(all P<0.05),there were significant differences.In the experimental group,Ⅰ～Ⅳ degree of hemoglobin decrease and the rate of diarrhea were 49.0%、31.4%,also lower than the control group(58.0%、46.0%respectively),but there was no significant difference(P>0.05).The two groups before treatment in patients with CD4 +(Th)cell percentage,CD8 +(Ts)percentage and CD4 +/CD8 + index compared with no significant difference(P>0.05),after treatment,the experimental group compared with before treatment,CD4+,CD4 +/CD8 + were significantly increased,there were significant differences(P<0.05).While the control group,compared with before treatment,there was no significant difference(P>0.05)in CD4 + percentage and CD4 +/CD8 + index.Two groups of CD8+percentage compared with before treatment showed no significant difference(P>0.05).The ratio of cost effectiveness in experimental group on efficiency rate and KPS were(3231.46and 1819.31),lower than the control group(4204.18 and 3214.96).Conclusion In patients with advanced small cell lung cancer chemotherapy,AiDi injection has prevention and treatment effect for bone marrow inhibition and gastrointestinal reaction.It can reduce the side effects of chemotherapy,improve clinical symptoms,improve quality of life and the clinical benefit rate,adjust blood T cell subsets CD4 + and CD8 +percentage,improve the cellular immune function.At the same time,pharmacoeconomic analysis showed that the experimental group had a better cost-effectiveness ratio.In summary,Aidi injection combined with IP is a better choice for the treatment of SCLC.